Safety of antidiabetes medications: An update

Individualizing Glycemic Targets in Type 2 Diabetes Mellitus: Implications of Recent Clinical Trials

(2013) Faramarz Ismail-Beigi et al.   ANNALS OF INTERNAL MEDICINE

Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors

(2013) A. E. Butler et al.   DIABETES

Insulin Therapy and Cancer

(2013) P. Home   DIABETES CARE

Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes

(2013) R. A. DeFronzo et al.   DIABETES CARE

A Critical Analysis of the Clinical Use of Incretin-Based Therapies: The benefits by far outweigh the potential risks

(2013) M. A. Nauck   DIABETES CARE

Interpreting Adverse Signals in Diabetes Drug Development Programs

(2013) C. J. Bailey   DIABETES CARE

Do GLP-1-Based Therapies Increase Cancer Risk?

(2013) M. A. Nauck et al.   DIABETES CARE

A Critical Analysis of the Clinical Use of Incretin-Based Therapies: Are the GLP-1 therapies safe?

(2013) P. C. Butler et al.   DIABETES CARE

An Analysis of Characteristics of Subjects Examined for Incretin Effects on Pancreatic Pathology

(2013) Evis Harja et al.   Diabetes Technology & Therapeutics

Mortality and Other Important Diabetes-Related Outcomes With Insulin vs Other Antihyperglycemic Therapies in Type 2 Diabetes

(2013) Craig J. Currie et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

(2013) William B. White et al.   NEW ENGLAND JOURNAL OF MEDICINE

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

(2013) Benjamin M. Scirica et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chronic GLP-1 Receptor Activation by Exendin-4 Induces Expansion of Pancreatic Duct Glands in Rats and Accelerates Formation of Dysplastic Lesions and Chronic Pancreatitis in the KrasG12DMouse Model

(2012) Belinda Gier et al.   DIABETES

The Human GLP-1 Analog Liraglutide and the Pancreas

(2012) Niels C.B. Nyborg et al.   DIABETES

Standards of Medical Care in Diabetes--2013

(2012)   DIABETES CARE

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETES CARE

Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia

(2012)   NEW ENGLAND JOURNAL OF MEDICINE

Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone: Interim report of a longitudinal cohort study

(2011) J. D. Lewis et al.   DIABETES CARE

High-density lipoprotein-cholesterol and not HbA1c was directly related to cardiovascular outcome in PROactive

(2011) E. Ferrannini et al.   DIABETES OBESITY & METABOLISM

Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies

(2011) Michael Elashoff et al.   GASTROENTEROLOGY

The Safety of Incretin-Based Therapies—Review of the Scientific Evidence

(2011) Daniel J. Drucker et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

GLP-1 and Calcitonin Concentration in Humans: Lack of Evidence of Calcitonin Release from Sequential Screening in over 5000 Subjects with Type 2 Diabetes or Nondiabetic Obese Subjects Treated with the Human GLP-1 Analog, Liraglutide

(2011) Laszlo Hegedüs et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Clinical Implications of the ACCORD Trial

(2011) S. Genuth et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Management of type 2 diabetes: new and future developments in treatment

(2011) Abd A Tahrani et al.   LANCET

Type 2 Diabetes: Assessing the Relative Risks and Benefits of Glucose-lowering Medications

(2010) Richard M. Bergenstal et al.   AMERICAN JOURNAL OF MEDICINE

Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents

(2010) Krystyna Tatarkiewicz et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Diabetes and Cancer: A consensus report

(2010) E. Giovannucci et al.   DIABETES CARE

Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation

(2010) Lotte Bjerre Knudsen et al.   ENDOCRINOLOGY

Insulin analogues and cancer risk: cause for concern orcause célèbre?

(2010) M. Pollak et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Does Insulin Therapy Promote, Reduce, or Have a Neutral Effect on Cancers?

(2010) Hertzel C. Gerstein   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Thiazolidinedione Use and the Longitudinal Risk of Fractures in Patients with Type 2 Diabetes Mellitus

(2010) Zeina A. Habib et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Severe Hypoglycemia and Risks of Vascular Events and Death

(2010) Sophia Zoungas et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bone Loss and Fracture Risk Associated with Thiazolidinedione Therapy

(2010) Daniel M Riche et al.   PHARMACOTHERAPY

Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide

(2009) David D. Dore et al.   CURRENT MEDICAL RESEARCH AND OPINION

Glucagon-Like Peptide-1 Receptor Activation Modulates Pancreatitis-Associated Gene Expression But Does Not Modify the Susceptibility to Experimental Pancreatitis in Mice

(2009) J. A. Koehler et al.   DIABETES

Beneficial Endocrine but Adverse Exocrine Effects of Sitagliptin in the Human Islet Amyloid Polypeptide Transgenic Rat Model of Type 2 Diabetes: Interactions With Metformin

(2009) A. V. Matveyenko et al.   DIABETES

From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus

(2009) R. A. DeFronzo   DIABETES

Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas

(2009) J. S. Nachnani et al.   DIABETOLOGIA

Does diabetes therapy influence the risk of cancer?

(2009) U. Smith et al.   DIABETOLOGIA

Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden

(2009) J. M. Jonasson et al.   DIABETOLOGIA

Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group

(2009) H. M. Colhoun et al.   DIABETOLOGIA

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

(2009) C. J. Currie et al.   DIABETOLOGIA

Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study

(2009) L. G. Hemkens et al.   DIABETOLOGIA

Diabetes and cancer

(2009) Paolo Vigneri et al.   ENDOCRINE-RELATED CANCER

Clinical Application of Incretin-Based Therapy: Therapeutic Potential, Patient Selection and Clinical Use

(2009) David M. Kendall et al.   European Journal of Internal Medicine

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

(2009) Philip D Home et al.   LANCET

Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis

(2008) Y. K. Loke et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Intensive Glucose Lowering in Type 2 Diabetes

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes

(2008) Rury R. Holman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes

(2008) William Duckworth et al.   NEW ENGLAND JOURNAL OF MEDICINE